The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over ...

Several large drugmakers will ask the Trump administration to pause Medicare drug-price negotiations, even as Biden-appointed ...

A longtime pharmaceutical executive laments the woeful state of the industry and calls for new leadership to win back public ...

The pharmaceutical industry’s biggest investment conference drew protesters in San Francisco Monday with signs reading “delay ...

The biopharmaceutical industry is cautiously optimistic about reversing last year's slump in investor returns. The sector faces uncertainties related to changes in US government policies, including ...

The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to ...

Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

The Indian pharmaceutical market (IPM) has returned to negative volume growth this Q3FY25 after two consecutive quarters of ...